



CancerStats II: Overview of available statistics for London

TCST-NCRAS Partnership Last updated: 4th February 2019



Introduction to Cancerstats II

From the CancerStats home page:

"The CancerStats portal has been designed to **give providers** of various types of cancer data **rapid**, **quality feedback** on the quality of their submissions. It allows users to look at the **completeness of key data items** and to **conduct comparisons** with local, regional and national averages to calculate relative performance. The portal will be a continued development, incorporating useful metrics and measures **with the aim of improving the quality of data** flowing to the National Cancer Registration and Analysis Service (NCRAS) and ultimately, **informing improvements in patient care and outcomes**.

The implementation of the CancerStats portal will be managed by the NCRAS directly with its data providers. The principal approach will be to work in partnership with clinicians and their information, management and multi-disciplinary teams."

Introduction to Cancerstats II

- CancerStats II is the new website for CancerStats data. As well as presenting cancer metrics available on CancerStats I (e.g. incidence, mortality, survival) it will include a wider range of more bespoke reports.
- This is possible because NCRAS can create new reports without the need for developer input.
- Note: Currently pages may still be in development and new reports are added regularly. Reports under development are marked as such.
- CancerStats II is used as a portal for NCRAS to feedback to Trusts and other NHS
 organisations in as close to real time as possible.
- As with CancerStats I, users need to register for an account before being granted access.
- Users must adhere to information governance rules to protect patient identification if using CancerStats data involving small numbers.
- Available at: https://cancerstats.ndrs.nhs.uk

01 cosd

COSD Reports

Level 1: Data Submissions

Indicator of whether submissions are made in required format and timelines

Level 2: Data Completeness

Completeness of key data items submitted by providers

Level 3: Data Summary

Allows user to create bespoke analysis of cancer metrics using selections/filters based on cancer registration records

Reports

Summary and stage reports

Site Specific COSD

Age analyses of haematological cancers/sarcomas

CTYA

Completeness of data items submitted on CTYA cancers

Pathology

Submitted pathology counts by Trust


Regional Completeness

Regional comparisons of Level 2 (completeness) data


Level 1 Data Submissions: London 2018



COSD Audits RTDS SACT Cascade LAPCD Guidance CADEAS My account Log out



Level 2 Data Completeness: London 2018



Level 3 Data Analysis: Selected London CCGs 2017



02 Audits

Audit reports available in CancerStats II

National Audit of Breast Cancer in Older Patients (NABCOP)

- Data Completeness (Cancer Alliance and Trust-level; 2014-2018)
- Data Analysis (Trust-level; 2014-2016)
- Quarterly Report of completeness (Cancer Alliance; 2014-2018)

National Lung Cancer Audit (NLCA)

- Data Submission timeliness and format (Trust-level; 2013-2019)
- Data Completeness (London, Cancer Alliance and Trust; 2014-2018)
- Data Analysis (Cancer Alliance and Trust-level; 2015-2016)
- Quarterly Report of completeness (PDF)

National Prostate Cancer Audit (NPCA)


- Data Submission timeliness and format (Trust-level; 2013-2019)
- Data Completeness (London, Cancer Alliance and Trust; 2014-2018)

Ovarian Cancer Audit


In development (2018)

All audits utilise data routinely collected through COSD, but may also collect some additional data items

NABCOP Data Analysis: Screening category, London Trusts 2014 -16




NABCOP Data Analysis: ER Status, London Trusts 2014 -16




Generated graphs can be downloaded as stand-alone images


NLCA Data Analysis: Stage at diagnosis, London 2016



NLCA Data Analysis: Treatment modality, London 2016



NPCA Data Submissions, London 2018



NPCA Data Completeness, London 2018




O3 Radiotherapy Dataset (RTDS)


RTDS Reports

- Data Submissions
 Indicates whether Trusts have submitted RTDS data
- Events (Attendances, Episodes and Prescriptions)
 Number of radiotherapy treatment events measured as attendances, episodes and prescriptions
- Radiotherapy machines (Attendances, working day profile)
 Describes levels of radiotherapy machine use
- Treatment codes
 Attendances by HRG or OPCS treatment code
- Intensity-Modulated Radiation Therapy
 Describes levels of IMRT use

RTDS Data Submissions, London 2018




COSD Audits RTDS SACT Cascade LAPCD Guidance CADEAS My account Log out




RTDS Events (Attendances), London 2018



RTDS Radiotherapy machine use, Brachytherapy London 2018



RTDS Treatment codes, London 2018



RTDS Intensity-Modulated Radiation Therapy, London 2018



O4 Systemic Anti-Cancer Therapy (SACT)

SACT Reports

Total activity (SACT vs SUS)

Comparison of patient numbers in SACT to those in Secondary Uses Service dataset

Data submissions

Measures Trust performance against requirement to upload and map regimen names to nationally recognised name without errors

Data completeness (London & Trust-level; 2017-18)

Measures Trust performance against requirement for data completeness for certain data items


National Dose banding (London & Trust level)

Describes SACT drugs administered inside/outside national dose banding

CTYA Data Report (London & Trust-level; 2017-18)

Report on children, teenagers and young adults receiving systemic anti-cancer therapy

SACT Data Submissions, London 2017-18



Trust performance against SACT data upload process requirements, by upload month

Trust Name	Upload Critical Errors Unmapped		Unresolved		1 -4 - 4		
rust Name	Month	%	Regimens	seineuD	Late Uploads	Late Approvals	
Barking Havering And Redbridge University	05/2017	0.0%		-	D	D	
Barking Havering And Redbridge University	08/2017	0.0%	0	D	D	D	
Barking Havering And Redbridge University	02/2018	0.0%	D	D	D	D	
Barking Havering And Redbridge University	07/2017	0.0%	D	D	D	D	
Barking Havering And Redbridge University	09/2017	0.0%	D	D	D	D	
Barking Havering And Redbridge University	06/2018		D	D	D	D	
Barking Havering And Redbridge University	04/2018	0.0%	D	D	D		
Barking Havering And Redbridge University	11/2017	0.0%	D	D	D	D	
Barking Havering And Redbridge University	03/2017	0.0%			D	D	
Barking Havering And Redbridge University	03/2018	0.0%	D	D	D	D	
Barking Havering And Redbridge University	06/2017	0.0%			D	D	
Barking Havering And Redbridge University	01/2018	0.0%	D	D	D	D	
Barking Havering And Redbridge University	01/2017	0.0%			D	D	
Barking Havering And Redbridge University	02/2017	0.0%			D	D	
Barking Havering And Redbridge University	04/2017	0.0%			D	D	
Barking Havering And Redbridge University	10/2017	0.0%	D	D	D	D	
Barking Havering And Redbridge University	05/2018	0.2%	D	D	D		
Barking Havering And Redbridge University	12/2017	0.0%	D	D	D	D	
Barts Health NHS Trust	09/2017	D.3%	143	D	D	D	


Data Completeness, London 2017

Selections: date, geography, age group, tumour group

Outputs: performance status and treatment intent, performance status completeness, <u>perf. status and treatment intent by</u> tumour group, height and weight,




These graphs show the completeness of performance status and treatment intent by tumour site. The target is 95%.




Breast 99.5% Gynae 99.4% Lung 99.3% Lower GI 99.1% Not grouped by SACT 98.8% Upper GI 98.8% Sarcoma 97.5% Urology 97.2% Lymphoma 96.9% Brain and CNS 96.4% Leukemia 96.2% Other 96.0% Head and Neck 95.7% Myeloma 95.6% Skin Haematology (Misc) 20% 80% 40% 60% 100%

Completeness of Performance Status by Tumour Site




SACT National Dose Banding, London 2017

Selections: date, drug, geography, age group **Outputs:** comparison drug inside/outside band, outside band, inside/outside band by Trust,



Children, teenagers and young adults receiving systemic anti-cancer Report, London 2017

Selections: date, age, geography, paediatric service, paediatric tumour, TYA service, TYA tumour **Outputs:** Counts (patient/ tumour/ regimen), activity by organisation/age/weekday, paediatric tumours by age, gender and age breakdown, regimen and drug summaries, regimen/drug by Trust, regimen/drug by gender




O5Life After Prostate CancerDiagnosis (LAPCD)

LAPCD Reports

- The LAPCD reports summarise over 100 questions in the LAPCD patient questionnaire alongside response rates
- Data are available at Trust, National and UK level
- Report: Gives results of all questions with categorised answers
- Survey Results: Gives results of all scored questions

LAPCD - Trust level summaries



LAPCD – Scored questions summary



COSD Audits RTDS SACT Cascade LAPCD Guidance CADEAS My account Log out

Home » Life After Prostate Cancer Diagnosis » Survey Results

Selections: questions where response is scored on a scale (e.g. from 0 - 5) **Outputs:** Trust-level summary of score

Score for social distress

Statistical Score

Score for social distress; 2014-2016

Nation	▲ Trust new	Number that answered survey	Number that answered this question	Score mean	Score standard deviation	Score median	Score minimum	Score maximum	
England	Airedale NHS Foundation Trust	159	153	2.4	4.1	1.0	0.0	25.0	
England	Dorset County Hospital NHS Foundation Trust	281	271	2.3	4.0	1.0	0.0	30.3	
England	Barnsley Hospital NHS Foundation Trust	142	133	4.0	6.0	1.0	0.0	29.0	
England	Barts Health NHS Trust	310	290	4.0	6.0	1.0	0.0	37.0	
England	Norfolk And Norwich University Hospitals NHS Foundation Trust	689	674	2.4	4.2	1.0	0.0	30.0	
England	Dudley Group NHS Foundation Trust	320	306	3.0	5.0	1.0	0.0	32.0	
England	Blackpool Teaching Hospitals NHS Foundation Trust	274	269	3.7	5.4	1.0	0.0	32.3	
England	Bolton NHS Foundation Trust	186	179	3.8	6.3	1.0	0.0	39.0	
England	Bradford Teaching Hospitals NHS Foundation Trust	132	128	3.2	5.4	0.0	0.0	27.0	
England	Brighton And Sussex University Hospitals NHS Trust	356	339	3.1	5.1	1.0	0.0	35.0	
England	Buckinghamshire Healthcare NHS Trust	361	353	2.6	5.0	0.0	0.0	32.0	
England	North Bristol NHS Trust	381	368	2.5	4.5	0.0	0.0	30.4	
England	East Cheshire NHS Trust	77	75	1.7	2.7	0.0	0.0	11.0	
England	Bedford Hospital NHS Trust	246	239	2.9	5.4	0.0	0.0	30.6	
England	Central Manchester University Hospitals NHS Foundation Trust	117	112	3.7	5.5	2.0	0.0	31.0	
England	Chelsea And Westminster Hospital NHS Foundation Trust	53	50	3.8	7.5	0.5	0.0	35.0	
England	Chesterfield Royal Hospital NHS Foundation Trust	308	294	3.4	5.7	1.0	0.0	43.6	
England	Christie NHS Foundation Trust	88	86	2.0	4.1	0.0	0.0	24.0	
England	City Hospitals Sunderland NHS Foundation Trust	334	319	3.8	6.2	1.0	0.0	41.0	
England	Colchester Hospital University NHS Foundation Trust	592	578	2.7	5.2	0.0	0.0	44.0	
England	Countess Of Chester Hospital NHS Foundation Trust	174	170	2.8	5.3	0.0	0.0	30.0	

O6 CADEAS

CADEAS cancer metrics on CancerStats II

- CADEAS aim to produce a series of reports on cancer metrics for Cancer Alliances
- These reports are intended to help Cancer Alliances identify variation and make evidence-based decisions for their cancer transformation programmes
- CCG and STP-level data is also provided for certain cancer metrics
- These reports are currently in the development and testing stages so may be updated frequently in the near future

CADEAS cancer metrics on CancerStats II

Section 1: Summary Statistics

Summary data tables of cancer metrics presented in reports (Alliance, CCG)

Section 2: Operational Performance

Two week wait & 62-day wait: metadata, cross-sections and trends (Alliance, STP, CCG)

Section 3: Prevention

Obesity & smoking prevalence: metadata, cross-sections and trends (Alliance, STP, CCG)

Section 4: Screening

Screening uptake & coverage statistics: metadata, cross-sections and trends (Alliance, STP, CCG)

Section 5: Early diagnosis

Early stage diagnoses & emergency presentations: metadata, cross-sections and trends (Alliance, STP, CCG)

Section 6: Diagnostics

Diagnostic waiting times / inpatient procedures / emergency admissions: metadata, cross-section and trends (Alliance, STP, CCG)

CADEAS cancer metrics on CancerStats II

Section 7: Treatment

In development

Section 8: Outcomes

One year net survival / Under 75 mortality: metadata, cross-section (Alliance, STP & CCG) and trends (CCG)

Section 9: Living With and Beyond Cancer

In development

Section 10: Patient Experience


Results from CPES questionnaire (2016 & 2017): metadata, results (CCG)

Section 11: COSD Level 3


User-defined outputs using cancer registrations data (Same as COSD level 3 data summary)

Section 1: Summary Statistics, London 2018


Central London




Section 2: 62 Day Wait Trends, London 2018




Section 3: Obesity prevalence NC & NE London 2017-18




Section 4: Bowel Screening coverage trends, London 2010-2018



Section 5: Early diagnosis trends, London 2011-2017




Section 6: Emergency admissions trends, London 2011-2017



compared to England (2016) Selections: geography, year Outputs: mortality distribution, mortality rates (cross-section & trends) Home » CADEAS » 8a: Mortality U75 cancer mortality distribution Metadata Data table U75 cancer mortality: Cross-section U75 cancer mortality: Trends Introduction Select Cancer Alliance: Select year: South East London 2012 2013 2014 U75 age-standardised cancer mortality rate per 100,000: 20 most commonly diagnosed cancers and CNS ~ Select a geography from the top selection box - from a choice of England overall, Cancer Alliance, STP or CCG Select England, Cancer Alliance, STP or CCG for comparison: ~ You can then compare the Under 75 cancer mortality distribution with another geography of your choice ~ Age-standardisation has been applied, meaning differences that you see will not be based on age. Other population and patient characteristics have not been controlled for, **ENGLAND** U75 age-standardised cancer mortality rate per 100,000: 20 most commonly diagnosed cancers on Hodgkin's Lymph Cancer Leukaemia Brain Head Uterus Of and Lung Breast Colorectal Prostate Ovary Pancreas and Liver Unknown Neck CNS Primary

Section 8: Under 75 mortality distribution 2016, SE London

Section 10: Patient experience survey results at CCG level



The National Cancer Patient Experience Survey (CPES) results

Question number 🔺	Question text	RAG A	Value	RAG VS	
	uud dada ruora			expected range	
1	Before you were told you needed to go to hospital about cancer, how many times did you see your GP (family doctor) about the health problem caused by cancer?	Within expected range	80.0	2	
2	How do you feel about the length of time you had to wait before your first appointment with a hospital doctor?	Within expected range	80.0	2	
5	Beforehand, did you have all the information you needed about your test?	Within expected range	94.0	2	
6	Overall, how did you feel about the length of time you had to wait for your test to be done?	Within expected range	90.0	2	
7	Were the results of the test explained in a way you could understand?	Within expected range	80.0	2	
8	When you were first told that you had cancer, had you been told you could bring a family member or friend with you?	Within expected range	71.0	2	
9	How do you feel about the way you were told you had cancer?	Within expected range	84.0	2	
10	Didyou understand the explanation of what was wrong with you?	Within expected range	76.0	2	
11	When you were told you had cancer, were you given written information about the type of cancer you had?	Within expected range	72.0	2	
12	Before your cancer treatment started, were your treatment options explained to you?	Within expected range	80.0	2	
13	Were the possible side effects of treatment(s) explained in a way you could understand?	Within expected range	74.0	2	
14	Were you offered practical advice and support in dealing with the side effects of your treatment(s)?	Within expected range	68.0	2	
15	Before you started your treatment(s), were you also told about any side effects of the treatment that could affect you in the future rather than straight away?	Within expected range	58.0	2	
16	Were you involved as much as you wanted to be in decisions about your care and treatment?	Within expected range	76.0	2	
17	Were you given the name of a Clinical Nurse Specialist who would support you through your treatment?	Within expected range	95.0	2	
18	How easy or difficult has it been for you to contact your Clinical Nurse Specialist?	Worse than expected range	75.0	3	
10	Withou you have had important auactions to acknow of this of himse Operation to have you and answers you could understand?	Waran than armostad range	70.0	η	

07 Planned releases

Upcoming Data Releases on CancerStats II

- Cancer incidence crude and age-standardised rates:
 Will be available to coincide with 2017 cancer registrations update
- Cancer mortality crude and age-standardised rates:
 Will be available to coincide with 2017 cancer registrations update
- Treatment modality
- Stage at diagnosis